281 related articles for article (PubMed ID: 18476530)
1. [The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas].
Feng C; Li HZ; Yan WG; Gao JG; Xu WF; Luo YF; Cao JL
Zhonghua Wai Ke Za Zhi; 2007 Dec; 45(24):1697-700. PubMed ID: 18476530
[TBL] [Abstract][Full Text] [Related]
2. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
[TBL] [Abstract][Full Text] [Related]
3. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior.
Brown HM; Komorowski RA; Wilson SD; Demeure MJ; Zhu YR
Cancer; 1999 Oct; 86(8):1583-9. PubMed ID: 10526289
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas.
Nagura S; Katoh R; Kawaoi A; Kobayashi M; Obara T; Omata K
Mod Pathol; 1999 Dec; 12(12):1107-11. PubMed ID: 10619262
[TBL] [Abstract][Full Text] [Related]
7. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma.
Tavangar SM; Shojaee A; Moradi Tabriz H; Haghpanah V; Larijani B; Heshmat R; Lashkari A; Azimi S
Pathol Res Pract; 2010 May; 206(5):305-9. PubMed ID: 20189725
[TBL] [Abstract][Full Text] [Related]
9. [Distinction between benign and malignant pheochromocytomas].
Liu TH; Chen YJ; Wu SF; Gao J; Jiang WJ; Lu ZH; Guan J; Wei SZ; Luo YF; Cao JL; Wan JW
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):198-202. PubMed ID: 15256107
[TBL] [Abstract][Full Text] [Related]
10. A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma.
Sangoi AR; McKenney JK
Am J Surg Pathol; 2010 Mar; 34(3):423-32. PubMed ID: 20154585
[TBL] [Abstract][Full Text] [Related]
11. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast.
Kleer CG; Giordano TJ; Braun T; Oberman HA
Mod Pathol; 2001 Mar; 14(3):185-90. PubMed ID: 11266524
[TBL] [Abstract][Full Text] [Related]
12. Stathmin as a marker for malignancy in pheochromocytomas.
Björklund P; Cupisti K; Fryknäs M; Isaksson A; Willenberg HS; Akerström G; Hellman P; Westin G
Exp Clin Endocrinol Diabetes; 2010 Jan; 118(1):27-30. PubMed ID: 19449284
[TBL] [Abstract][Full Text] [Related]
13. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
[TBL] [Abstract][Full Text] [Related]
14. Elevated levels of telomerase activity in malignant pheochromocytoma.
Kubota Y; Nakada T; Sasagawa I; Yanai H; Itoh K
Cancer; 1998 Jan; 82(1):176-9. PubMed ID: 9428495
[TBL] [Abstract][Full Text] [Related]
15. [Immunohistochemistry expression of 3 markers (CEA, UEA-I and Ki-67) in nasal inverted papillomas].
De Gabory L; Deminière C; Stoll D
Rev Laryngol Otol Rhinol (Bord); 2008; 129(3):159-65. PubMed ID: 19694158
[TBL] [Abstract][Full Text] [Related]
16. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling.
Suh I; Shibru D; Eisenhofer G; Pacak K; Duh QY; Clark OH; Kebebew E
Ann Surg; 2009 Dec; 250(6):983-90. PubMed ID: 19661783
[TBL] [Abstract][Full Text] [Related]
17. Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66.
Guillemot J; Thouënnon E; Guérin M; Vallet-Erdtmann V; Ravni A; Montéro-Hadjadje M; Lefebvre H; Klein M; Muresan M; Seidah NG; Anouar Y; Yon L
J Mol Endocrinol; 2012 Apr; 48(2):115-27. PubMed ID: 22217803
[TBL] [Abstract][Full Text] [Related]
18. Expression of galectin-3, nm-23, and cyclooxygenase-2 could potentially discriminate between benign and malignant pheochromocytoma.
Saffar H; Sanii S; Heshmat R; Haghpanah V; Larijani B; Rajabiani A; Azimi S; Tavangar SM
Am J Clin Pathol; 2011 Mar; 135(3):454-60. PubMed ID: 21350102
[TBL] [Abstract][Full Text] [Related]
19. [The expression and significance of chromogranin A and synaptophysin in adrenal gland tumors].
Feng C; Li HZ; Yan WG; Luo YF; Cao JL
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):486-8. PubMed ID: 16188147
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of Ki-67 antigen expression in non-Hodgkin's lymphomas.
Szczuraszek K; Mazur G; Jeleń M; Dziegiel P; Surowiak P; Zabel M
Anticancer Res; 2008; 28(2A):1113-8. PubMed ID: 18507062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
